Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

127.00 +0.12 (+0.09%)
Official Closing Price Updated: 4:10 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,105,084
Open 126.82
Bid (Size) 126.65 (15)
Ask (Size) 127.00 (6)
Prev. Close 126.88
Today's Range 125.35 - 127.59
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
Via Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals. 
Via InvestorPlace

Performance

YTD
+12.15%
+12.15%
1 Month
+1.35%
+1.35%
3 Month
+5.97%
+5.97%
6 Month
+23.27%
+23.27%
1 Year
+9.54%
+9.54%

More News

Read More
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
3 Under-The-Radar Stocks With Positive Potential
Via Talk Markets
Unveiling 17 Analyst Insights On Merck & Co
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Topics Stocks
Exposures US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Via The Motley Fool
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
1 New Green Flag for Moderna and Merck Stock
Via The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Via Benzinga
Exposures COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Via Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Via Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
Via Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
Via InvestorPlace
Topics Retirement
Exposures Pension
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.